RECORD // Company

Neumora Therapeutics, Inc.

Built 2026-11-21T11:36:41Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Neumora Therapeutics, Inc. · Ctgov · same registered legal name as 'Neumora Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • NEUMORA THERAPEUTICS INC · Epa echo · same registered legal name as 'Neumora Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • NEUMORA THERAPEUTICS INC · Epa echo · same registered legal name as 'Neumora Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

7 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001193125-26-462194

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-34,440,0003 months ended 2026-09-3010-Q2026-11-160001193125-26-4621942026-11-21 11:36 UTCReport an error
Interest expense$1,442,0003 months ended 2026-09-3010-Q2026-11-160001193125-26-4621942026-11-21 11:36 UTCReport an error
Cash and cash equivalents$85,654,000at 2026-09-3010-Q2026-11-160001193125-26-4621942026-11-21 11:36 UTCReport an error
Debt due in the next 12 months$0at 2026-09-3010-Q2026-11-160001193125-26-4621942026-11-21 11:36 UTCReport an error
Debt due in year 2$0at 2026-09-3010-Q2026-11-160001193125-26-4621942026-11-21 11:36 UTCReport an error
Debt due in year 3$0at 2026-09-3010-Q2026-11-160001193125-26-4621942026-11-21 11:36 UTCReport an error
Debt due in year 4$58,170,000at 2026-09-3010-Q2026-11-160001193125-26-4621942026-11-21 11:36 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001885522
Ticker
NMRA
EIN
844367680
CUSIP
640979100
Record ID
sx:sec:0001885522

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

32 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
Business address260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 024722026-11-16SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-236,928,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:36 UTCReport an error
Total assets (at 2025-12-31)$191,047,0002025-12-3110-K, XBRL Assets2026-11-21 11:36 UTCReport an error
Stockholders' equity (at 2025-12-31)$103,871,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:36 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$182,530,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:36 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-206,440,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:36 UTCReport an error
Long-term debt (at 2025-12-31)$54,532,0002025-12-3110-K, XBRL LongTermDebt2026-11-21 11:36 UTCReport an error
Form D total offering amount (D filed 2023-01-03)$474,356,9882023-01-03D2026-11-21 11:36 UTCReport an error
Form D total amount sold (D filed 2023-01-03)$474,356,9882023-01-03D2026-11-21 11:36 UTCReport an error
Form D industry groupBiotechnology2023-01-03D2026-11-21 11:36 UTCReport an error
Form D revenue rangeDecline to Disclose2023-01-03D2026-11-21 11:36 UTCReport an error
Form D date of first sale2020-09-082023-01-03D2026-11-21 11:36 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-16)On November 16, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02 of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference…2026-11-16SEC EDGAR 8-K 0001193125-26-462165 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-14)On August 14, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the second quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02 of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in…2026-08-14SEC EDGAR 8-K 0001193125-26-350349 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-07-27)On July 27, 2026, Neumora Therapeutics, Inc. (the “Company”) issued a press release announcing favorable pre-clinical toxicology results from NMRA-215. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.2026-07-27SEC EDGAR 8-K 0001193125-26-316819 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
Plan (pension, plan no. 001)NEUMORA THERAPEUTICS 401(K) PLAN: 165 participants, assets $17,104,8822025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:36 UTCReport an error
Plan (welfare, plan no. 501)NEUMORA THERAPEUTICS, INC. HEALTH & WELFARE PLAN: 98 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:36 UTCReport an error
Largest institutional holder #1 (13F as filed): Siren, L.L.C.$14,446,2972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$13,246,1782026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #3 (13F as filed): SOFTBANK GROUP CORP.$10,353,5122026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$7,938,2952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #5 (13F as filed): MIC Capital Management UK LLP$7,583,1902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #6 (13F as filed): FMR LLC$5,948,0772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #7 (13F as filed): WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST$5,625,5092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #8 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$4,433,3412026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #9 (13F as filed): ICONIQ Capital, LLC$4,350,4532026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #10 (13F as filed): TWO SIGMA INVESTMENTS, LP$3,816,2092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.